Novartis drug Afinitor significantly extended time without disease progression in women with HER2...
14 hrs ago | drugs.com
• Everolimus plus trastuzumab and vinorelbine met primary endpoint of extending PFS compared to placebo plus trastuzumab and vinorelbine after prior therapy[1] • Results of Phase III trial, BOLERO-3, first to show...
Read more...
HER2 Afinitor breast cancer everolimus Novartis Votubia BOLERO-3 vinorelbine trastuzumab mTOR